Vanguard Global Advisers
MTNB icon

Vanguard Global Advisers’s Matinas BioPharma MTNB Stock Holding History

Vanguard Global Advisers’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$819 Hold
1,338
– – ﹤0.01% 3624
2026
Q1 		$669 Buy
+1,338
New +$837 ﹤0.01% 3649

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Vanguard Global Advisers's MTNB Position: Q2 2026 in Review

Vanguard Global Advisers held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 1,338 shares worth $819. The position accounts for ﹤0.01% of the portfolio, ranked #3624.

Vanguard Global Advisers first reported a position in MTNB in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Vanguard Global Advisers held 1,338 shares of Matinas BioPharma worth $819 as of Q2 2026.
  • Vanguard Global Advisers left its Matinas BioPharma share count unchanged in Q2 2026.
  • Matinas BioPharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3624 holding.
  • Vanguard Global Advisers first reported a position in Matinas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.